Skip to main content

Table 2 Sensitivity and specificity in the training set and test set

From: Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: a case-control study

Patient group Training set Test set
Tested Positive Sensitivity (%) Specificity (%) Tested Positive Sensitivity (%) Specificity (%)
Early stage 23 19 82.6% (61.2–95.0%)   26 17 65.4% (44.3–82.8%)  
Late stage 20 18 90.0% (68.3–98.8%)   16 15 93.8% (69.8–99.8%)  
All cancer 43 37 86.0% (72.2–94.8%)   42 32 76.2% (60.5–87.9%)  
Benign 5 1 20.0% (0.5–71.4%) 80.0% (28.4–99.5%) 5 1 20.0% (0.5–71.4%) 80.0% (28.4–99.5%)
Healthy control 62 3   95.2% (86.5–99.0%) 63 3   95.2% (86.7–99.0%)
All non-cancer 67 4   94.0% (85.5–98.3%) 68 4   94.1% (85.7–98.4%)